Senzime Annual Summary 2018

Report this content

News: Uppsala, April 25, 2019. Senzime AB’s (publ) annual summary for 2018 in English is now available on the company’s webbsite

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                    

Tel: +46 (0)70-813 34 17, email:                        

Jessica Roxhed, CFO

Tel: +46 (0)703-94 94 98, e-mail: 


About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399,, is Certified Adviser for Senzime.